| Type: | mab |
| Source: | u |
| Target: | Notch 2, Notch 3 |
| Legal Status: | Investigational |
| Cas Number: | 1359940-55-8 |
| Atc Prefix: | none |
| Kegg: | D11775 |
| Chemspiderid: | none |
| C: | 6338 |
| H: | 9804 |
| N: | 1700 |
| O: | 1990 |
| S: | 48 |
| Unii: | 333YMY788E |
| Synonyms: | OMP-59R5 |
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]